Amgen Inc. (NASDAQ:AMGN) Holdings Raised by Davidson Trust Co.

Davidson Trust Co. grew its holdings in Amgen Inc. (NASDAQ:AMGNFree Report) by 4.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,733 shares of the medical research company’s stock after purchasing an additional 72 shares during the period. Davidson Trust Co.’s holdings in Amgen were worth $466,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in AMGN. Moneta Group Investment Advisors LLC increased its holdings in Amgen by 83,875.6% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock worth $1,980,571,000 after buying an additional 7,532,031 shares during the last quarter. Norges Bank acquired a new position in Amgen in the fourth quarter worth approximately $1,351,778,000. Price T Rowe Associates Inc. MD increased its holdings in Amgen by 158.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,950,013 shares of the medical research company’s stock worth $774,791,000 after buying an additional 1,806,456 shares during the last quarter. Morgan Stanley increased its holdings in Amgen by 12.9% in the fourth quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock worth $3,493,471,000 after buying an additional 1,523,665 shares during the last quarter. Finally, Franklin Resources Inc. increased its holdings in Amgen by 50.7% in the second quarter. Franklin Resources Inc. now owns 3,290,926 shares of the medical research company’s stock worth $730,651,000 after buying an additional 1,106,980 shares during the last quarter. Institutional investors and hedge funds own 74.44% of the company’s stock.

Amgen Stock Down 0.3 %

Shares of NASDAQ:AMGN traded down $1.02 during trading on Thursday, hitting $294.85. 5,945,438 shares of the company’s stock traded hands, compared to its average volume of 3,019,862. Amgen Inc. has a 52 week low of $211.71 and a 52 week high of $329.72. The company has a current ratio of 2.86, a quick ratio of 2.56 and a debt-to-equity ratio of 7.71. The company has a market cap of $157.80 billion, a price-to-earnings ratio of 23.69, a price-to-earnings-growth ratio of 2.84 and a beta of 0.62. The company has a 50-day moving average price of $294.42 and a 200-day moving average price of $273.66.

Amgen (NASDAQ:AMGNGet Free Report) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, beating the consensus estimate of $4.66 by $0.05. The business had revenue of $8.20 billion for the quarter, compared to analysts’ expectations of $8.13 billion. Amgen had a return on equity of 152.15% and a net margin of 23.83%. Amgen’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $4.09 EPS. As a group, research analysts forecast that Amgen Inc. will post 19.81 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 7th. Shareholders of record on Friday, February 16th will be paid a $2.25 dividend. This is a boost from Amgen’s previous quarterly dividend of $2.13. The ex-dividend date is Thursday, February 15th. This represents a $9.00 annualized dividend and a yield of 3.05%. Amgen’s payout ratio is presently 68.21%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. The Goldman Sachs Group increased their price target on Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a report on Wednesday. BMO Capital Markets raised Amgen from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $286.00 to $326.00 in a research report on Tuesday, December 19th. Morgan Stanley reduced their target price on Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a research report on Wednesday. Royal Bank of Canada raised their target price on Amgen from $303.00 to $329.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft started coverage on Amgen in a research report on Thursday, November 9th. They issued a “hold” rating and a $240.00 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $295.30.

Check Out Our Latest Stock Report on AMGN

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 2,096 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $273.03, for a total transaction of $572,270.88. Following the transaction, the senior vice president now owns 10,874 shares of the company’s stock, valued at approximately $2,968,928.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.46% of the company’s stock.

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Read More

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.